What are the most common peptides in males?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Male Peptides

The most common peptides in males include B-type natriuretic peptide (BNP), relaxin family peptides, and growth hormone-releasing peptides, with BNP being particularly significant for cardiovascular health monitoring.

Natriuretic Peptides

  • B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are important cardiac biomarkers that are naturally produced in the heart, primarily in the ventricles during cardiac stress 1
  • BNP is primarily produced by cardiac myocytes and fibroblasts in response to myocardial stretch mediated by pressure and volume 1
  • Normal BNP levels in males are typically lower than in females:
    • Young adult males: <25 pg/ml 1
    • Males 45-59 years: <100 pg/ml 1
    • Males >60 years: <98 pg/ml 1
  • Males consistently have lower BNP levels than females, likely due to androgen suppression of pro-BNP synthesis 1

Relaxin Family Peptides

  • Relaxin is an important peptide in males that is produced in the male reproductive tract and is present in semen 1
  • In males, relaxin increases sperm motility and enhances penetration into oocytes 1
  • INSL3 (Insulin-like peptide 3) is another important relaxin family peptide in males that acts on RXFP2 receptors 1
  • RXFP2 receptors are found in the testis, specifically in spermatocytes, spermatids, Leydig cells, and epididymal epithelium 1
  • INSL3/RXFP2 signaling plays a critical role in testicular descent, as evidenced by bilateral cryptorchidism in INSL3 and RXFP2 knockout mice 1

Growth Hormone-Related Peptides

  • Growth hormone-releasing peptides (GHRPs) are synthetic peptides with potent stimulatory effects on growth hormone secretion 2, 3
  • Common GHRPs include sermorelin, GHRP-2, GHRP-6, ibutamoren, and ipamorelin 3
  • Sermorelin is a 29-amino acid analogue of human growth hormone-releasing hormone (GHRH) that stimulates growth hormone secretion from the anterior pituitary 4
  • GHRPs act through specific receptors at both pituitary and hypothalamic levels 2, 5
  • These peptides can significantly improve body composition by reducing fat and increasing muscle mass in hypogonadal males 3

Clinical Significance

  • BNP and NT-proBNP are crucial biomarkers for diagnosing and monitoring cardiac conditions, particularly heart failure 1
  • Elevated BNP levels are associated with increased risk of perioperative mortality and morbidity 1
  • Higher body mass index results in lower normal values of BNP, which is an important consideration when interpreting results in overweight or obese males 1
  • Androstenedione, while not a peptide but a steroid hormone, serves as a precursor to testosterone and is sometimes measured alongside other hormones when evaluating male reproductive disorders 6

Therapeutic Applications

  • GHRPs have emerged as potential adjunctive therapies for symptoms of hypogonadism, particularly for improving body composition 3
  • Sermorelin at doses of 1 μg/kg bodyweight intravenously can be used as a diagnostic test for growth hormone deficiency 4
  • Some GHRPs are orally active, making them potentially convenient therapeutic options 5
  • The combination of GHRPs with GHRH produces synergistic effects on growth hormone release 5

Monitoring Considerations

  • When measuring BNP levels in males, age-specific reference ranges should be used for proper interpretation 1
  • Factors that can affect BNP levels include age, renal function, and body mass index 1
  • Regular monitoring of BNP may be valuable in males with cardiovascular risk factors or established heart disease 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Growth hormone-releasing peptides.

European journal of endocrinology, 1997

Research

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999

Guideline

Androstenedione: Clinical Significance and Health Risks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.